WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Website Related Website Development Monday, March 30, 2026 
Add Press Release News | News Feeds Feeds | Email This News Email


Signant Health Appoints Internationally Recognized Cognitive Assessment Expert John Harrison to Further Advance Innovation in CNS Clinical Trials
Friday, November 7, 2025

PHILADELPHIA, Oct. 30, 2025 /PRNewswire/ -- Signant Health, the leader in evidence generation for modern clinical trials, announced today the appointment of John Harrison as Clinical Vice President. As drug developers face growing demand for sophisticated cognitive endpoints in Alzheimer's disease and dementia trials, John's 25+ years of expertise in helping sponsors integrate cognitive testing into drug development programs further strengthens Signant's clinically driven solutions for complex neuroscience studies.

"The field of neuroscience clinical research is experiencing unprecedented innovation, particularly in early Alzheimer's disease where precise cognitive assessment is critical to demonstrating drug efficacy," said John Harrison. "I'm excited to join Signant at this pivotal time and work alongside the team to advance how we measure and interpret cognitive outcomes in CNS trials. Signant's commitment to scientific rigor and its deep therapeutic expertise make it the ideal partner for sponsors developing the next generation of neurological treatments."

John will work closely with Signant's David Miller, a renowned expert in Alzheimer's and other dementias and co-author of the ADAS-Cog scoring manual, to strengthen the company's cognitive assessment capabilities. His role will focus on driving innovation in clinical outcome assessments for CNS trials, with particular emphasis on Alzheimer's disease, dementia, and complex neurological conditions where cognitive endpoints play a central role in regulatory decision-making.

John brings extensive experience partnering with pharmaceutical and biotechnology companies to design and implement cognitive testing strategies in clinical trials. He holds dual academic appointments at Amsterdam UMC in the Netherlands and King's College London in the United Kingdom, where his research focuses on optimizing cognitive assessment methodologies for drug development. His deep understanding of both the scientific and operational challenges in neuroscience trials will directly benefit Signant's customers as they navigate increasingly complex regulatory requirements for cognitive endpoints.

"John's appointment reinforces our commitment to advancing clinical trial science in one of the most challenging and important therapeutic areas," commented Dawie Wessels, Signant's Chief Medical Officer. "His scientific expertise and practical experience working with sponsors on cognitive assessment strategies will enhance our ability to deliver solutions that capture the high-quality evidence needed for regulatory submissions in Alzheimer's and CNS drug development. This is exactly the kind of specialized knowledge our customers need as they work to bring innovative treatments to patients with neurological conditions."

To learn more about Signant Health and its full range of eclinical solutions, visit: https://www.signanthealth.com/

About Signant Health

Signant Health is the evidence generation company. We are focused on leveraging software, deep therapeutic and scientific knowledge, and operational expertise to consistently capture, aggregate, and reveal quality evidence for clinical studies across traditional, virtual, and hybrid trial models. For more than 20 years, over 600 sponsors and CROs of all sizes - including all Top 20 pharma - have trusted Signant solutions for remote and site-based eCOA, EDC, eConsent, RTSM, supply chain management, and data quality analytics. Learn more at www.signanthealth.com.

Contact:

Heather Bilinski
media@signanthealth.com
+1 610.400.4141

Photo - https://mma.prnewswire.com/media/2808582/John_Harrison.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/signant-health-appoints-internationally-recognized-cognitive-assessment-expert-john-harrison-to-further-advance-innovation-in-cns-clinical-trials-302598815.html

SOURCE Signant Health



Email This News Email | Submit To Slashdot Slashdot | Submit To Digg.com Digg | Submit To del.icio.us Del.icio.us | News Feeds Feeds

RELATED NEWS ARTICLES
Nav Asetek - Mandatory Notification of Trade | Jan 22, 2026
Nav Tomorrowland Brings the Magic to Shanghai for a Spectacular First Indoor Edition in China | Jan 22, 2026
Nav Rent Manager Earned Best Real Estate Software Product Award and Multiple Review Badges from G2 Platform | Jan 22, 2026
Nav BC.GAME to Host "Stay Untamed" Night During Abu Dhabi's Packed Web3 Summit Week | Jan 22, 2026
Nav Auburn University's Applied Research Institute Expands Advanced Manufacturing Capabilities with CF3D Enterprise Cell | Jan 22, 2026
Nav AMPERA ANNOUNCES LOCATION FOR GLOBAL HEADQUARTERS | Jan 22, 2026
Nav Gemmy Alerts Customers: Fake Websites Target Holiday Decorators | Jan 22, 2026
Nav California Divorce Mediation Center Unveils Modern Website Redesign | Jan 22, 2026
Nav Culture and tourism sectors thrive in Xiamen | Jan 22, 2026
Nav AMPLIFY Named Finalist in Three Categories at the 2026 Golden Gavel Awards | Jan 22, 2026
NEWS SEARCH

FEATURED NEWS | POPULAR NEWS
Submit News | View More News View More News